Perastin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perastin

What is Perastin?

Perastin is a pharmacological treatment utilized in the management of chronic inflammatory conditions, specifically targeting the underlying biological pathways that contribute to tissue swelling and pain. As a therapeutic agent, it belongs to a class of medications designed to modulate the immune system's response to perceived injury or long-term irritation.

Mechanism of Action

The primary function of Perastin involves the stabilization of cellular membranes and the inhibition of specific enzymes responsible for the production of inflammatory mediators. By reducing the synthesis of these chemical signals, the medication helps to decrease the recruitment of immune cells to affected areas. This process assists in limiting the progression of inflammation and helps maintain the integrity of surrounding healthy tissues.

Primary Uses

Perastin is typically indicated for patients experiencing persistent inflammatory symptoms that have not responded sufficiently to basic lifestyle modifications or first-line supportive care. Its application is most common in cases involving:

  • Joint and Soft Tissue Inflammation: Reducing localized heat and swelling associated with chronic degenerative changes.
  • Systemic Inflammatory Responses: Assisting in the management of conditions where the body’s immune system remains in an overactive state.
  • Post-Acute Recovery: Supporting the stabilization of tissues following a severe inflammatory flare.

Characterization

Unlike immediate-acting analgesics that only mask pain, Perastin is characterized by its focus on the biological drivers of inflammation. It is considered a maintenance-oriented therapy, meaning its effects are generally observed over a period of consistent use rather than providing instant relief. It is provided in formulations designed for steady absorption to ensure consistent levels of the active compound remain present in the bloodstream.

What side effects are possible with Perastin?

Possible Side Effects and Safety Information

The safety profile for Perastin (Pravastatin) is defined by adverse reactions classified by frequency and the body system affected, based on official regulatory documents. This information is intended to describe the officially documented risks, not to provide instruction or medical advice.

Frequency-Classified Adverse Reactions

Adverse reactions are classified into several frequency tiers:

  • Common (ge 1/100 to < 1/10): Typically include headache, dizziness, certain gastrointestinal effects like nausea, vomiting, or diarrhea, and musculoskeletal pain (myalgia).
  • Uncommon (ge 1/1,000 to < 1/100): May involve skin reactions (rash, pruritus), sleep disturbances, and peripheral nerve effects.
  • Rare (ge 1/10,000 to < 1/1,000): The most clinically significant events fall into this tier, including myopathy (muscle disease) and rhabdomyolysis (severe muscle breakdown), as well as hepatitis or pancreatitis.

Serious Safety Considerations

The regulatory profile highlights several serious adverse reactions, which, while rare, are explicitly documented. These include rhabdomyolysis (a potentially fatal muscle disorder), severe hepatic failure, and reports of immune-mediated necrotizing myopathy (IMNM). Furthermore, some patients have reported cognitive impairment (memory loss, confusion), which is generally noted as being reversible upon treatment discontinuation.

Restrictions and Special Populations

Official labeling imposes strict safety limitations. Perastin is contraindicated (must not be used) in patients with active liver disease or unexplained, persistently elevated liver enzymes. It is also contraindicated during pregnancy due to the potential for fetal harm and is not recommended during breastfeeding. Advanced age and the presence of renal impairment are recognized as risk factors that may predispose individuals to muscle-related adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents state that experience with overdosage of Perastin (Pravastatin) is limited. The most serious, dose-related toxicities documented in the prescribing information involve the musculoskeletal and renal systems, including Rhabdomyolysis (severe muscle breakdown) and subsequent Acute renal failure (acute kidney injury). Other potential manifestations of severe exposure or toxicity include Myopathy (muscle disease) and Elevated LFTs (liver enzyme elevations).

Required Emergency Action

Immediate medical attention must be sought for any suspected overdose. Official guidance mandates contacting emergency services (e.g., 911) or a Poison Control center if the affected individual has collapsed, experienced a seizure, is having trouble breathing, or cannot be awakened. This instruction reflects the risk of severe, life-threatening outcomes documented in regulatory warnings.

Official Management and Treatment

The regulatory approach confirms that no specific antidote is known or available for Pravastatin overdose. Treatment is strictly limited to symptomatic and supportive measures instituted as required by the patient’s clinical status. Monitoring, such as checking Creatine Kinase levels, may be required when myopathy is suspected. Hemodialysis is generally not considered beneficial due to the high protein binding of the active ingredient.

Therapeutic Uses of Perastin

What Perastin Treats: Main Uses and Benefits

Perastin is commonly used when short-term symptomatic assistance is needed across specific symptomatic and clinical domains. It is applied across domains where additional symptomatic support is needed. It is considered relevant in clinical contexts where supportive symptom management is appropriate.

Supportive Symptom Management

Perastin is considered relevant for easing symptoms related to heightened physiological activity and symptoms that interfere with daily functioning. This medication is commonly used across conditions presenting with acute episodes. In contexts marked by increased discomfort or tension, it may assist with managing groups of symptoms that appear suddenly or fluctuate.

Functional Stability and Well-being

Applied during phases of increased distress or discomfort, the medication provides support that helps ease the overall symptom burden. It may assist with maintaining functional stability when symptoms are more noticeable and supports general well-being during symptomatic phases. It is relevant in contexts involving heightened systemic burden and may help patients cope more steadily with symptom fluctuations.

Quick Fact: This medication may assist with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview of Perphenazine

Eligibility and Restrictions for Use

Who Can and Cannot Use Perastin? (Pravastatin)

Category Official Regulatory Status
Approved Populations Adults and Pediatric patients aged 8 years and older (specifically for Heterozygous Familial Hypercholesterolemia).
Contraindicated Groups Active liver disease (including unexplained persistent elevation of liver enzymes) and known Hypersensitivity to the medicine.
Conditional Use Groups Patients with severe renal impairment or uncontrolled hypothyroidism require special caution due to increased risk factors.
Reproductive Status Pregnancy is a major restriction, and use during Lactation is not recommended.

Eligibility Structure Summary

The official eligibility profile is strictly defined by major regulatory agencies. Use is absolutely contraindicated in patients with active liver disease and those with hypersensitivity to the drug. The medicine is not established for use in children younger than 8 years. Additionally, specific populations, including older adults and those with renal impairment, are noted as having predisposing factors for myopathy, requiring a cautious approach as defined in the regulatory labeling. The medicine is also not recommended for use in combination with Gemfibrozil.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formal Regulatory Restrictions

Co-administration of Perastin is formally prohibited with Systemic Fusidic Acid and its derivatives, including within seven days of discontinuing treatment. The concomitant use of the fibrate Gemfibrozil is strictly avoided due to the significantly increased risk of severe muscle toxicity, including rhabdomyolysis.

Exposure-Modifying Interactions

The plasma concentration of Perastin is substantially increased by certain medicinal products. Cyclosporine, for example, causes a marked rise in drug levels due to the inhibition of hepatic uptake transporters. Other agents, including Macrolide antibiotics like Clarithromycin, are also documented to increase exposure. Conversely, Bile Acid Sequestrants (such as Cholestyramine or Colestipol) inhibit absorption, requiring Perastin to be administered at least 1 hour before or 4 hours after the resin.

Additive Risk and Predisposing Factors

Co-administration with agents such as Niacin (Nicotinic Acid), Colchicine, and other Fibrates results in a documented additive risk of myopathy. This risk of muscular adverse effects when co-administered with interacting drugs is officially noted to be higher in patients with renal impairment, uncontrolled hypothyroidism, or advanced age. Large amounts of alcohol are also associated with an increased risk of liver damage.

Mechanism of Action

How Perastin Works

Perastin (Pravastatin) exerts its action through highly hepatoselective inhibition of cholesterol synthesis. Due to its hydrophilic nature, the drug concentrates primarily in the liver, relying on specific membrane transporters for uptake. The molecule functions as a competitive inhibitor of the enzyme HMG-CoA reductase, which controls the rate-limiting step in the mevalonate pathway of cholesterol biosynthesis. This molecular interaction curtails the synthesis of new cholesterol inside the hepatocyte.

This reduction in intracellular cholesterol triggers a compensatory feedback mechanism: liver cells increase the density and number of LDL receptors on their surface. This systemic consequence increases the liver’s ability to scavenge and clear Low-Density Lipoprotein Cholesterol (LDL-C) from the bloodstream, resulting in reduced plasma lipid concentrations. A secondary mechanistic consequence of this enzyme inhibition is the reduced production of isoprenoid intermediates, which is associated with the physiological consequence of modulating endothelial function.

Dosage and Administration Information

How to Use Perastin — Administration Guidelines

This section describes the procedural guidelines for using Perastin tablets.

Administration Scope Instruction
Route of administration Oral.
Dosing schedule The maximum recommended dose for adults is 80 mg once daily. The standard initial dose for adult use is typically 40 mg once daily.
Timing in relation to meals May be taken as a single dose at any time of the day, with or without food.
Preparation requirements None.
Age-group administration rules For pediatric patients aged 8 to 13 years, the recommended dose is 20 mg once daily. For adolescents aged 14 to 18 years, the recommended starting dose is 40 mg once daily.
Missed-dose rules If a dose is missed, it should be taken as soon as remembered. If it is nearly time for the subsequent dose, the missed dose should be skipped to prevent doubling.
Special procedural conditions The drug must be used as an adjunct to a prescribed standard cholesterol-lowering diet. For patients with severe renal impairment, the recommended starting dose is 10 mg once daily, and the maximum is limited to 40 mg daily. When co-administered with a bile acid-binding resin, the tablet must be taken at least one hour before or four hours after the resin. The maximum daily dose is limited to 20 mg when taken with cyclosporine.

Instruction Classifications (High-Level)

Administration method type Oral.
Frequency pattern Daily (once daily).
Use-context constraints Dietary adherence; Temporal spacing relative to bile acid resins; Dose reduction requirements for specific patient conditions.

Resulting Procedural Structure

Step sequence:

  • Initiate treatment only after starting and maintaining a standard cholesterol-lowering diet.
  • Administer the prescribed dose orally as a single dose once daily.
  • Maintain the dose for a minimum of four weeks before considering adjustment.
  • Follow specific dose limitations for co-administration with other drugs or in cases of severe renal impairment.

Connection to the overall use protocol: Instructions establish a standardized protocol for chronic, once-daily oral use that is always accompanied by mandatory dietary therapy. Dosing is structured, requiring specific initial amounts and adherence to a minimum four-week interval for any dosage change, ensuring a controlled titration process.

Recent Clinical Evidence

Perastin: Recent Clinical Evidence

Clinical development for Perastin has centered on its potential role in modulating inflammatory pathways, particularly in conditions related to chronic neurological impairment and certain types of pain. Its investigational mechanism of action involves targeting a specific inflammatory cytokine, which researchers hypothesize may reduce neuroinflammation and oxidative stress.

Efficacy Findings

Phase 2 and 3 clinical trials have been conducted to evaluate Perastin's efficacy against placebo in adult patients with chronic post-stroke impairments. A pivotal, randomized, double-blind, placebo-controlled trial, though prematurely halted due to funding, involved over 120 participants. The study's primary analysis showed no statistically significant difference between the Perastin group and the placebo group concerning the primary outcome, which was a change in quality of life measures (e.g., the SF-36v2 total score) at 28 days post-administration.

However, some earlier, smaller observational studies have documented reports of improvement in various post-stroke impairments following treatment. These reports, while not confirming definitive efficacy, have contributed to ongoing research interest.

Safety and Tolerability Profile

Across multiple studies, Perastin has generally demonstrated a tolerability profile similar to placebo during the 28-day observation period. The proportion of serious adverse events was reported to be similar in both the active treatment and placebo arms in the randomized trials. No specific signals of unexpected toxicity were reported in the main studies. The medication's continued use and long-term safety profile are subjects of ongoing investigation, and evidence from the specific clinical context indicates that it does not pose an additional risk of noncardiovascular serious adverse events beyond what is expected for the patient population studied.

Frequently Asked Questions (FAQ)

Common questions about Perastin (FAQ)


Q: What is the main difference between Perastin and other similar medicines I see advertised?

Perastin (Pravastatin) is officially described as a hydrophilic, or water-soluble, statin. This characteristic is noted in regulatory documents because it influences how the medication is primarily distributed to and concentrated in the liver. This characteristic is one difference noted compared to some other statin drugs that are more lipophilic (fat-soluble).


Q: Is Perastin a type of antibiotic or steroid?

No. Perastin is officially classified as an HMG-CoA reductase inhibitor, belonging to the class of medications commonly known as statins. These agents are used for their ability to lower lipids and cholesterol in the blood, and they are distinct from both antibiotics and steroids.


Q: How quickly should I expect to notice any effect after starting Perastin?

The drug is intended as a long-term therapy to help manage lipid levels over time. Official clinical studies have measured the maximum therapeutic effect on cholesterol reduction after at least four weeks of continuous treatment. Consistent adherence to the prescribed regimen is necessary for the intended effects to fully manifest.


Q: Will taking Perastin make me feel sleepy or affect my ability to drive?

Adverse events reported in official safety profiles include common events like dizziness and headache, and less common reports of sleep disturbances. No specific official restriction on operating machinery is mandated; however, individuals should observe their reaction to the medication.


Q: Can people with a history of heart problems use Perastin?

Official documents indicate that Perastin is used to address cardiovascular risk. It is used to reduce the risk of major cardiovascular events, such as heart attack and stroke, in patients who have a history of heart disease, as well as those considered high-risk due to multiple factors.


Q: Why does the label warn about grapefruit juice?

Official regulatory information for Perastin specifically notes that, unlike certain other statin medicines, its chemical structure is not significantly affected by the enzyme inhibited by grapefruit juice. For this reason, official labeling typically does not require a restriction on grapefruit consumption when taking Perastin.


Q: Can I stop taking Perastin suddenly if I feel better?

Official information emphasizes that Perastin is prescribed as a long-term therapy to continuously manage cholesterol and lipid levels. Stopping the medication prematurely may lead to a rise in lipid levels, which could increase the risk of related cardiovascular events. It is important to continue treatment unless a healthcare provider directs otherwise.


Q: What should I tell my dentist before a procedure if I am taking Perastin?

Official labeling advises that patients may need to temporarily stop using the medication if they are scheduled for major surgery or develop other serious health problems. Official guidance suggests informing all healthcare professionals, including dentists, that you are currently taking Perastin.


Q: How long does Perastin stay in your system after stopping it?

Pharmacokinetic studies indicate that Perastin is eliminated from the body relatively quickly. It has a short half-life, meaning it is substantially cleared from the bloodstream within a few hours after the last dose.


Q: What is the likelihood of drug dependence with Perastin?

Official regulatory documents and safety profiles do not list Perastin as having any potential for drug dependence or abuse. It is not classified as an addictive substance.


Q: Why is it sometimes taken at night versus in the morning?

The official label states the medication may be taken as a single dose at any time of day. However, taking it in the evening may sometimes be suggested to align the drug's action with the body’s natural rhythm of cholesterol production, which is highest at night.


Q: Can Perastin cause changes in mood or anxiety levels?

The official safety profile has documented rare reports of cognitive impairment, such as memory loss or confusion. However, specific changes related to 'mood' or 'anxiety' are not explicitly listed in the common or serious adverse event categories.


Q: Does Perastin affect birth control pills?

Official regulatory documents do not list any known drug interaction between Perastin and oral contraceptive agents (birth control pills). This indicates that the medication does not typically affect the effectiveness of oral contraceptives.

--ุท

Q: Is Perastin considered a 'high-risk' medicine?

Official documents require the drug to be dispensed with specific warnings concerning rare but serious events, such as rhabdomyolysis and liver failure. It is contraindicated in specific patient groups, indicating it carries defined risks that require careful management and oversight by a healthcare professional.


Q: Are there any known long-term effects of taking Perastin for many years?

The long-term effects of Perastin are established through clinical trials that have followed patients for up to several years, confirming its cardiovascular benefits and safety profile over time. The safety of long-term use is continually monitored through post-marketing surveillance as defined by regulatory bodies.


Q: Can I use Perastin if I have a history of seizures?

Official regulatory documentation does not list a history of seizures as an absolute contraindication for use. However, some pre-existing conditions may increase the risk of muscle or kidney problems, which may require caution or dose adjustment as advised by a physician.


Q: Are there generic versions of Perastin available?

Yes. Perastin is the brand name for the active ingredient Pravastatin, which is widely available in generic versions as Pravastatin Sodium tablets.


Q: What happens if I accidentally take more Perastin than prescribed?

Regulatory documents indicate that acute overdose reports have been rare. Adverse reactions following overdose have been non-specific, and the management is generally supportive. Official guidance for overdosage involves supportive management; individuals are instructed to seek medical attention.


Q: Is Perastin safe to use during pregnancy or while breastfeeding?

Official labeling states that the drug is contraindicated (must not be used) during pregnancy due to the potential for harm to the fetus. It is also not recommended during breastfeeding because of the potential risk of serious adverse reactions in the infant.


Q: Is it normal to feel a mild headache when first starting Perastin?

Yes. According to clinical trial reports published in official documents, headache is classified as one of the 'Common' adverse reactions. This means it has been reported in a higher percentage of patients compared to less common side effects.


Q: What should I do if a side effect seems to be getting worse?

Official guidance instructs patients to immediately report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or fatigue, as these are signs of serious potential side effects. Any serious symptoms, such as signs of liver damage, should also be immediately reported.


Q: Are there specific warnings for children taking Perastin?

Official documents specify that use in children is limited to those 8 years and older with Heterozygous Familial Hypercholesterolemia. The official adverse reaction profile observed in these children was generally noted to be similar to the profile seen in adults.


Q: Are there any specific laboratory tests that are affected by Perastin?

Yes. Official documents state that the drug can cause elevations in serum transaminases (liver enzymes) and Creatine Phosphokinase (CPK) levels. Monitoring may be advised during treatment, particularly if signs of liver injury or muscle problems develop, to check for official laboratory abnormalities.


Q: Can older adults use Perastin without increased risks?

Official geriatric use data found no overall difference in efficacy compared to younger patients. However, regulatory documents recognize advanced age as a predisposing factor for muscle-related adverse effects (myopathy), which requires a cautious approach under professional guidance.


Q: Does alcohol consumption affect how Perastin works?

Official regulatory information specifies that use is contraindicated in patients with active liver disease. While moderate alcohol use is not prohibited, excessive consumption is recognized as potentially predisposing individuals to muscle-related side effects.


Q: What research evidence supports the use of Perastin?

The use of Perastin as a lipid-lowering agent is supported by large, long-term, randomized clinical trials. These studies demonstrated its ability to significantly reduce LDL-C levels and, critically, reduce the risk of major coronary events and stroke.


Q: What is the maximum duration of treatment mentioned in clinical trials?

Clinical trials supporting the drug's approved uses have followed patients for extended periods, with some key studies lasting approximately 4 to 5.8 years. These findings established the efficacy and safety profile necessary for chronic, long-term use.


Q: Do I need to get blood tests done while I am taking Perastin?

Yes. Official labeling recommends that liver enzyme tests (transaminases) be performed prior to starting the drug. Monitoring may be advised during treatment, particularly if signs of liver injury or muscle problems develop, to check for official laboratory abnormalities.


Q: What is the purpose of the black box warning on Perastin, if it has one?

Official documentation, specifically the FDA label for Perastin (Pravastatin), does not contain a Black Box Warning. This is a distinguishing feature compared to some other drugs in different classes that may have one.


Q: What is the difference between a common side effect and a serious one?

Official documentation classifies a 'Common' side effect (e.g., headache) as occurring in ge 1/100 to < 1/10 patients. A 'Serious' safety consideration is an adverse reaction that is potentially life-threatening or requires immediate intervention, such as rhabdomyolysis or severe hepatic failure, typically classified as 'Rare' or 'Uncommon'.


Q: What if I have diabetes; can I still use Perastin?

Regulatory documents indicate that a small increase in blood sugar (HbA1c) and an increased risk of new-onset diabetes have been reported with statin drugs. However, regulatory documents indicate that the cardiovascular benefits generally support continued use.

How should Perastin be stored and disposed of?

How to Store and Dispose of Perastin (Pravastatin Sodium)

Official regulatory guidelines strictly define the storage and disposal requirements for Pravastatin tablets to maintain product integrity and safety.

Storage Conditions

Requirement Official Standard
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Must be protected from moisture and light and kept in a tightly closed, light-resistant container.
Child Safety Keep this and all drugs out of the reach of children, typically in a child-resistant closure.

Disposal Instructions

Unused or expired Pravastatin tablets must be disposed of in accordance with local requirements for pharmaceutical waste. Patients should consult a healthcare professional or pharmacist for specific instructions, as throwing the medicine into household trash or wastewater is generally not recommended by regulatory bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perastin found in:

A-Z Index: